Genomics News & Analysis | Business 2.0
APOE4 Study Links Wnt Signaling to Disrupted Brain Insulation
How to Evaluate Human Genomic Data Before Research Reuse
AlphaGenome's Research Value Depends on What Happens After Prediction
Illumina and Precision Medicine Push Genomics Into Routine Care
Guardant360 Liquid CDx Broadens Blood-Based Genomic Testing
AI in Genomics Explained: What Enterprises Need to Know in 2026
Vertex Wins FDA Nod to Give Casgevy CRISPR Therapy to Toddlers
AWS Showcases AI Role in Genomics at Symposium
FDA: Gene-Editing Sponsors Can Reuse Platform Data Across Programs
PacBio: Sub-$300 HiFi Genome Resets Long-Read Sequencing Economics
Illumina vs Guardant vs Natera: The MRD Market Landscape 2026
Illumina 2026: Distributed WGS MRD Kit Lands Ahead of ASCO
Inside Illumina's 2026 Genomics Pivot — And What Rivals Are Doing
The Quiet Genetics Infrastructure Shift Illumina and CRISPR Therapeutics
Beyond the Sequencer: What Genomics ROI Actually Looks Like in 2026
Genetics in 2026: Illumina and CRISPR Therapeutics Expose a Widening
Why Pharma Groups Are Scaling Genomics in 2026, Led by Illumina and Roche
Top Genetics Investment Priorities for 2026, According to Illumina, Thermo Fisher and Roche
Why Biotech Companies Are Accelerating Genomics Adoption in 2026, Led by Illumina, Thermo Fisher and Ginkgo
Why Healthcare Is Accelerating Genetics in 2026, Led by Roche and Illumina